ClinicalTrials.gg
RecruitingNCT07633847PROCEEDUpdated Nov 20, 2026

A Post Market Trial Assessing the Accuracy of Normal Mode Reading vs. ProScan Reading With the NaviCam SB System. This is a Comparison of Retrospectively Obtained Capsule Endoscopy Videos With a New AI Reading Tool; no New Interventions Will be Completed.

An observational study in Small Bowel Bleeding, sponsored by AnX Robotica Corp.. Recruiting at 3 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by AnX Robotica Corp. · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 20, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
92
Ages
22 Years and older
Sex
All
01

Study summary

NaviCam ProScan is an artificial intelligent (AI) assisted reading tool designed to aid small bowel capsule endoscopy reviewers in decreasing the time to review capsule endoscopy images for adult patients in whom the capsule endoscopy images were obtained for suspected small bowel bleeding.

Read the detailed description

The clinician is responsible for conducting their own assessment of the findings of the AI-assisted reading through review of the entire video, as clinically appropriate. ProScan also assists small bowel endoscopy reviewers in identifying the digestive tract location (oral cavity and beyond, esophagus, stomach, small bowel) of the image in adults. The tool is not intended to replace clinical decision making.

02

Conditions studied

  • Small Bowel Bleeding

Keywords

  • artificial intelligent
  • assisted reading tool
  • capsule endoscopy
03

In context

Lead sponsor

AnX Robotica Corp. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults 22 years old or older

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of all genders, races, ethnicities and geographical backgrounds, from 22 years of age or older.
  • Patient agrees to sign and follow all study procedures.

Exclusion criteria

Exclusion Criteria:

  • In patients with known or suspected gastrointestinal obstruction, strictures, or fistulas based on the clinical picture or pre-procedure testing and profile.
  • In patients with cardiac pacemakers or other implantable electronic medical devices (MR unsafe devices only).
  • In patients with dysphagia with high risk of aspiration.
  • In pregnant women.
  • GI motility issues (gastroparesis)
  • GI dysmotility
  • Chronic opioid usage
  • Requires endoscopic placement
  • In patients with endoscopic within one week of scheduled capsule ingestion
  • No NSAID use within 14 days of scheduled capsule ingestion
  • No GLP-1 drugs within 7 days of scheduled capsule ingestion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
92 participants (estimated)
Target follow-up
14 Days
Patient registry
Yes

Groups and cohorts

  • NaviCam VCE (video capsule endoscopy)

    Adults 22 years of age or older who received a NaviCam capsule endoscopy procedure

    Device: Video capsule endoscopy · Other: Phase II = Data analysis by Independent Readers · Other: Phase III = Data Analysis by Expert Readers

Interventions

  • DeviceVideo capsule endoscopy

    Phase I = Data Collection. The video from the capsule endoscopy procedure will be reviewed and reported by the treating physician. Once the capsule has passed and any adverse events have been collected, there will be no additional patient follow-up.

  • OtherPhase II = Data analysis by Independent Readers

    Independent video capsule readers to review and evaluate the videos from the capsule endoscopy procedure (Phase I), plus the ProScan videos.

  • OtherPhase III = Data Analysis by Expert Readers

    An Expert Panel will read all videos to create a database comparing the Physician results (Phase I) and the ProScan + Physician results (Phase II).

06

What researchers measure

Primary outcomes

  1. Subject-level sensitivity

    Subject-level sensitivity will be evaluated for superiority of ProScan assistance versus unassisted assessments in the identification of patients with one or more true findings.

    Time frame: 24 months

  2. Subject-level specificity

    Subject-level sensitivity will be evaluated for non-inferiority of superiority of ProScan assistance versus unassisted assessments in the identification of patients with no ground truth findings.

    Time frame: 24 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 21 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 8, 2026
StartActual
Sep 8, 2026was Jun 2026
Primary completionEst.
Jun 15, 2028
CompletionEst.
Sep 15, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • NYU Langone Health · New York, United Statesno status→Recruiting
  • NYU Grossman School of Medicine · New York, United Statesno status→Recruiting
  • Digestive Health Associates of Texas · Bedford, United Statesno status→Recruiting
Nov 20, 2026
Start date
Jun 15, 2026→Sep 8, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • NYU Langone Health · New York, United Statesno status→Recruiting
    • NYU Grossman School of Medicine · New York, United Statesno status→Recruiting
    • Digestive Health Associates of Texas · Bedford, United Statesno status→Recruiting
    Start date Jun 15, 2026→Sep 8, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07633847
Lead sponsor
AnX Robotica Corp.
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Sep 8, 2026
Primary completion
Jun 15, 2028 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Tim Thomas, RAC
Contact
tim.thomas@anxrobotics.com
770-480-2911
Shabana Pasha, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion